Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...
Kim Newcomer, director of volunteers, Colorectal Cancer Alliance, shares findings from a survey on colorectal cancer care ...
Luminescent gold nanoparticles (L-AuNPs) represent a novel class of luminescent nanomaterials that have attracted ...
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...
A new research paper was published in Oncotarget, Volume 16, on February 12, 2025, titled “Could Panitumumab with very low ...
Furin is identified as the key enzyme responsible for cleaving the apelin precursor. Inhibiting this cleavage could serve as ...
Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors ...
Patients with metastatic cancer had better quality of life, clinical outcomes, and sense of well-being when they regularly ...
SAN FRANCISCO -- Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when ...
GlobalData on MSN4d
BMJ’s Phase III Opdualag study fails to meet endpointsThe combination therapy failed to beat out the company’s other cancer therapy, Opdivo, in patients living with melanomas.
Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...
Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback